How food and other meds affect a new TB drug
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests how a new TB drug (Sudapyridine) interacts with two common medicines: itraconazole (an antifungal) and rifampin (a TB treatment). It also looks at how food affects the drug. The study is for healthy Chinese adults to find the safest dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy Chinese adults, ages 18 to 50.
- Men must weigh at least 110 pounds (50 kg) and women must weigh at least 99 pounds (45 kg).
- No serious medical conditions (heart, liver, kidney, etc.) or recent surgeries that affect drug absorption.
- No use of certain medications, supplements, or grapefruit/pomelo products before or during the study.
- Must be willing to use effective birth control and avoid donating sperm or eggs for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests how a new drug called MDR-001 works when taken with two common medications (rifampin and itraconazole). Researchers want to understand if these drugs affect each other in healthy volunteers, which helps ensure the new drug is safe before testing it in patients.
Hear when a new Rifampicin-Resistant Pulmonary Tuberculosis Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.